The Medicines Company Steps Up Antibiotics Development with Rempex Purchase

By Heather Cartwright

Pharma Deals Review: Vol 2013 Issue 12 (Table of Contents)

Published: 23 Dec-2013

DOI: 10.3833/pdr.v2013.i12.1998     ISSN: 1756-7874

Section: Mergers & Acquisitions



In a deal potentially worth up to US$474 M, The Medicines Company (TMC) has acquired Rempex Pharmaceuticals to gain antibiotic programmes in varying stages of development that target three of the most common Gram-negative infections among seriously ill hospitalised patients...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details